Psyllium showed the clearest benefit for irritable bowel syndrome across 30 trials

Fiber is the first thing almost anyone with irritable bowel syndrome gets told to try. It is cheap, it is sold everywhere, and the advice has been standard for decades.

The evidence underneath it was overdue a look. Fiber supplementation is widely used and recommended for irritable bowel syndrome, however there is no recent evidence synthesis.

A team has now pooled 30 trials in Gastroenterology, and the answer splits in two: fiber helped, one fiber in particular, and a second way of measuring the same thing found nothing at all.

What irritable bowel syndrome is

Irritable bowel syndrome is a problem that affects the large intestine. It can cause abdominal cramping, bloating, and a change in bowel habits.

The change goes in different directions in different people. Some people with the disorder have constipation. Some have diarrhea. Others go back and forth between the two. That variation matters later.

It is common and poorly understood. It affects about twice as many women as men and is most often found in people younger than 45 years, and no one knows the exact cause. There is no specific test for it.

One piece of reassurance is worth stating early. Although IBS can cause a great deal of discomfort, it does not harm the intestines.

Treatment is therefore about symptoms. Most people diagnosed with IBS can control their symptoms with diet, stress management, probiotics, and medicine.

Why fiber is the obvious thing to try, and the obvious thing to doubt

Fiber is a substance in plants, and dietary fiber is the kind you eat. You may also see it listed on a food label as soluble fiber or insoluble fiber, and both types have important health benefits.

It does clear things a sluggish gut needs. Dietary fiber adds bulk to your diet, helps digestion and helps prevent constipation.

The catch is in the same source, and anyone with a sensitive gut already knows it. Increasing dietary fiber too quickly can lead to gas, bloating, and cramps.

Those are the symptoms of irritable bowel syndrome. A treatment whose main side effect is the condition it treats is one you would want good evidence for.

What the review pooled

The search was wide and the rules were set in advance. The researchers searched MEDLINE, Embase, Web of Science, and the Cochrane Central Register of Controlled Trials from inception to 9 April 2026, and registered the review prospectively on PROSPERO.

Registering a review before running it is the equivalent of pre-registering a trial: it stops the questions being chosen after the answers are visible.

The search identified 4008 records, and 30 RCTs were eligible including 1904 people with IBS, all comparing a fiber supplement against a suitable placebo control.

The fibers were not interchangeable. The most common fiber types were wheat bran (n=7), psyllium (n=6), inulin-type fructans (n=5), and B-GOS (n=2). Psyllium forms a gel; wheat bran does not; B-GOS, short for a prebiotic sugar chain, mostly feeds bacteria. Lumping them together is like pooling trials of three different drugs.

What counting responders showed

On the first outcome, fiber won. Sixteen RCTs reported clinical response, with 52% responding to fiber vs 44% to control.

Eight percentage points is the whole of it, and both halves of that comparison are worth reading. A response rate of 44% in people taking placebo is enormous, and typical of this condition. Irritable bowel syndrome responds strongly to being treated at all.

Against that background, moving to 52% is a real but modest gain: something like twelve or thirteen people taking fiber for one extra person to feel better than placebo would have made them.

One fiber did the work. There was benefit specifically for psyllium, at roughly half again the response rate of its controls, from six trials.

Wheat bran was the most-studied fiber in the set, with seven trials, and does not appear in that sentence.

What measuring symptoms showed

Then the second outcome, which points the other way.

Nine RCTs reported overall gastrointestinal symptoms using integrative scores, showing no significant effect, with the exception of B-GOS, which improved symptoms.

The same intervention, the same condition, a different way of asking. Counting how many people say they improved found a benefit. Measuring how much symptom burden changed did not.

Neither result is wrong. A responder analysis is sensitive to people crossing a threshold and blind to how far they moved; a severity score is the reverse. When the two disagree, the honest reading is that the effect is small enough for the choice of ruler to decide the answer.

The symptom-score analysis was also built on far fewer people, and the trials in it disagreed with each other a great deal, both of which widen the range of possibilities rather than narrowing them.

The question the field has not answered

The paper’s own frustration is about who fiber is for.

Subgroup analysis for IBS subtype was not possible for most outcomes. Constipation-predominant and diarrhea-predominant irritable bowel syndrome are close to opposite problems, and a bulking agent is not obviously the right answer to both.

If fiber helps one group and hurts another, pooling them produces exactly the muted average this review reports. The authors say as much in their recommendation: future RCTs should report outcomes for individual IBS subtypes or only recruit specific IBS-subtypes.

What this cannot tell you

A meta-analysis inherits the weaknesses of its trials. Many fiber trials are small, short, and hard to blind, because a patient can usually tell whether they are swallowing a bulking agent.

Doses, preparations and durations differ across 30 studies, and the review pools them.

And a clinical response is a patient saying they feel better, which is the right outcome for a symptom-defined condition and a soft one for comparing across trials that asked the question differently.

What to do if you have irritable bowel syndrome

If a fiber supplement is on the table, this evidence points at psyllium specifically, not fiber in general and not bran.

Start low and build up. Increasing dietary fiber too quickly can lead to gas, bloating, and cramps, and doing it slowly is the difference between tolerating a supplement and abandoning it in week one.

Expect a modest effect, and know that a good part of what you feel will be the same response the placebo groups had. That is not a trick; feeling better is feeling better. It is a reason to judge fiber against how it works for you rather than against the promise on the tub.

Psyllium’s other use has firmer ground under it. For chronic constipation specifically, viscous soluble fiber beat placebo on difficulty passing stool at high certainty, the strongest grade in that literature.

And get the diagnosis first. There is no specific test for irritable bowel syndrome, which means the label is applied after other things have been ruled out, and self-treating a symptom pattern that has not been looked at is the one genuinely risky move here.

The dietary route has a durability problem worth knowing about. A low-FODMAP diet reduces symptoms at six weeks, and in a trial that followed people for a year afterwards without support, the benefit had gone.